Abatacept: Difference between revisions
From IDWiki
(Created page with "* Small-molecule inhibitor of T cell activation * Formed of extracellular domain of the cytotoxic T lymphocyte-associated antigen 4 linked to the Fc portion of human IgG1 ** D...") |
No edit summary |
||
| Line 1: | Line 1: | ||
* |
* T-cell costimulation inhibitor |
||
* Formed of extracellular domain of the cytotoxic T lymphocyte-associated antigen 4 linked to the Fc portion of human IgG1 |
* Formed of extracellular domain of the cytotoxic T lymphocyte-associated antigen 4 linked to the Fc portion of human IgG1 |
||
** Decreases T cell activation |
** Decreases T cell activation |
||
* Indications include [[RA]] and [[JRA]] |
* Indications include [[RA]] and [[JRA]] |
||
* Infectious complications include [[Upper respiratory tract infection|upper respiratory tract infections]], and reports of [[pneumonia]], [[sepsis]], [[aspergillosis]], [[sinusitis]], [[candidiasis]], [[bronchitis]], [[cellulitis]], [[HSV]], and [[VZV]] |
* Infectious complications include [[Upper respiratory tract infection|upper respiratory tract infections]], and reports of [[pneumonia]], [[sepsis]], [[aspergillosis]], [[sinusitis]], [[candidiasis]], [[bronchitis]], [[cellulitis]], [[HSV]], and [[VZV]] |
||
[[Category:T-cell costimulation inhibitors]] |
|||
[[Category:Medications]] |
|||
Latest revision as of 01:16, 17 March 2022
- T-cell costimulation inhibitor
- Formed of extracellular domain of the cytotoxic T lymphocyte-associated antigen 4 linked to the Fc portion of human IgG1
- Decreases T cell activation
- Indications include RA and JRA
- Infectious complications include upper respiratory tract infections, and reports of pneumonia, sepsis, aspergillosis, sinusitis, candidiasis, bronchitis, cellulitis, HSV, and VZV
